More on HALO
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $68.57 |
|
|||
| Open | $69.25 | ||||
| 52 Wk High | $18.39 | ||||
| 52 Wk Low | $6.96 | ||||
| Day High | $69.25 | ||||
| Day Low | $67.02 | ||||
| P/E | N/A | ||||
| EPS | $-0.58 | ||||
| Volume | 3,654,032 | ||||
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Form 4 HALOZYME THERAPEUTICS, For: Jun 12 Filed by: Snyder Mark Howard
- Halozyme expects minimal Medicare pricing impact on royalties through 2035
- Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
- Form 3 HALOZYME THERAPEUTICS, For: Jun 08 Filed by: Snellgrove Darren
- Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Torley Helen
- Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
- Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Connaughton Bernadette
- JPMorgan Reinstates Halozyme Therapeutics (HALO) at Neutral
- Form 144 HALOZYME THERAPEUTICS, Filed by: LaBrosse Nicole
Entities mentioned with HALO
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
